FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058646840> ?p ?o ?g. }

• W2058646840 endingPage "122" @default.
• W2058646840 startingPage "114" @default.
• W2058646840 abstract "We observed the relief of hot flashes in breast cancer survivors taking tamoxifen and treated with sertraline for depression. Our objective was to assess the effect of sertraline on the frequency and severity of hot flashes, mood status, and health-related quality of life. We used a randomized, double-blind, placebo-controlled, crossover study using 6 weeks of sertraline (50 mg each morning) versus placebo. Study participants were 62 breast cancer survivors from an oncology clinic in a tertiary care center on adjuvant tamoxifen reporting bothersome hot flashes. Patients were asked to keep a daily hot flash diary to record hot flash frequency and severity, from which hot flash scores (frequency x severity) were calculated. The Center for Epidemiologic Studies depression scale and Functional Assessment of Cancer Therapy--Breast (FACT-B) (at baseline, 6 weeks, and 12 weeks) were used to assess mood and quality of life. Sixty-two women were accrued. Forty-seven women (median age 53.9 years, range 36.6-77.1 years; 89% postmenopausal; 85.5% Caucasian) completed the first 6 weeks and 39 completed 12 weeks. The baseline daily hot flash frequency and score were 5.8 (standard deviation 4.1) and 11.5 (14.0), respectively. At the end of the first 6 weeks, hot flash frequency decreased by 50% in 36% of those taking sertraline compared to 27% taking placebo. In the crossover analysis, sertraline was significantly more effective than placebo: women crossing from placebo to sertraline had a decrease (-0.9 and -1.7) in hot flash frequency and score, whereas those crossing from sertraline to placebo had an increase (1.5 and 3.4) in hot flash frequency and score (p = 0.03 and 0.03). Forty-eight percent preferred the sertraline period, 11% preferred the placebo period, and 41% had no preference (p = 0.006). Measures of depression and quality of life were within normal range and did not change significantly within treatment groups. Sertraline decreases hot flashes in breast cancer survivors taking tamoxifen and women prefer sertraline to placebo. Further study of sertraline for the management of hot flashes is warranted." @default.
• W2058646840 created "2016-06-24" @default.
• W2058646840 creator A5001088387 @default.
• W2058646840 creator A5007726590 @default.
• W2058646840 creator A5012306755 @default.
• W2058646840 creator A5059225709 @default.
• W2058646840 creator A5086431899 @default.
• W2058646840 date "2006-03-01" @default.
• W2058646840 modified "2023-10-17" @default.
• W2058646840 title "Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen" @default.
• W2058646840 cites W1558293110 @default.
• W2058646840 cites W1804627766 @default.
• W2058646840 cites W1865738444 @default.
• W2058646840 cites W1891596808 @default.
• W2058646840 cites W1932045453 @default.
• W2058646840 cites W1966623655 @default.
• W2058646840 cites W1973757681 @default.
• W2058646840 cites W1977398381 @default.
• W2058646840 cites W1979870292 @default.
• W2058646840 cites W1985527766 @default.
• W2058646840 cites W1987187456 @default.
• W2058646840 cites W1990244587 @default.
• W2058646840 cites W1996597481 @default.
• W2058646840 cites W2042805078 @default.
• W2058646840 cites W2047246104 @default.
• W2058646840 cites W2062202632 @default.
• W2058646840 cites W2092726363 @default.
• W2058646840 cites W2102556613 @default.
• W2058646840 cites W2105258029 @default.
• W2058646840 cites W2111093019 @default.
• W2058646840 cites W2112778345 @default.
• W2058646840 cites W2121134234 @default.
• W2058646840 cites W2130377362 @default.
• W2058646840 cites W2133675074 @default.
• W2058646840 cites W2141647078 @default.
• W2058646840 cites W2149671999 @default.
• W2058646840 cites W2321102288 @default.
• W2058646840 cites W2416917144 @default.
• W2058646840 cites W4210958476 @default.
• W2058646840 cites W4250017753 @default.
• W2058646840 doi "https://doi.org/10.1111/j.1075-122x.2006.00218.x" @default.
• W2058646840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16509835" @default.
• W2058646840 hasPublicationYear "2006" @default.
• W2058646840 type Work @default.
• W2058646840 sameAs 2058646840 @default.
• W2058646840 citedByCount "137" @default.
• W2058646840 countsByYear W20586468402012 @default.
• W2058646840 countsByYear W20586468402013 @default.
• W2058646840 countsByYear W20586468402014 @default.
• W2058646840 countsByYear W20586468402015 @default.
• W2058646840 countsByYear W20586468402016 @default.
• W2058646840 countsByYear W20586468402017 @default.
• W2058646840 countsByYear W20586468402018 @default.
• W2058646840 countsByYear W20586468402019 @default.
• W2058646840 countsByYear W20586468402020 @default.
• W2058646840 countsByYear W20586468402021 @default.
• W2058646840 countsByYear W20586468402022 @default.
• W2058646840 countsByYear W20586468402023 @default.
• W2058646840 crossrefType "journal-article" @default.
• W2058646840 hasAuthorship W2058646840A5001088387 @default.
• W2058646840 hasAuthorship W2058646840A5007726590 @default.
• W2058646840 hasAuthorship W2058646840A5012306755 @default.
• W2058646840 hasAuthorship W2058646840A5059225709 @default.
• W2058646840 hasAuthorship W2058646840A5086431899 @default.
• W2058646840 hasBestOaLocation W20586468401 @default.
• W2058646840 hasConcept C121608353 @default.
• W2058646840 hasConcept C126322002 @default.
• W2058646840 hasConcept C142724271 @default.
• W2058646840 hasConcept C159110408 @default.
• W2058646840 hasConcept C168563851 @default.
• W2058646840 hasConcept C204787440 @default.
• W2058646840 hasConcept C27081682 @default.
• W2058646840 hasConcept C2776128548 @default.
• W2058646840 hasConcept C2777176818 @default.
• W2058646840 hasConcept C2777669559 @default.
• W2058646840 hasConcept C2779177272 @default.
• W2058646840 hasConcept C2779951463 @default.
• W2058646840 hasConcept C2781161787 @default.
• W2058646840 hasConcept C530470458 @default.
• W2058646840 hasConcept C71924100 @default.
• W2058646840 hasConcept C87813604 @default.
• W2058646840 hasConceptScore W2058646840C121608353 @default.
• W2058646840 hasConceptScore W2058646840C126322002 @default.
• W2058646840 hasConceptScore W2058646840C142724271 @default.
• W2058646840 hasConceptScore W2058646840C159110408 @default.
• W2058646840 hasConceptScore W2058646840C168563851 @default.
• W2058646840 hasConceptScore W2058646840C204787440 @default.
• W2058646840 hasConceptScore W2058646840C27081682 @default.
• W2058646840 hasConceptScore W2058646840C2776128548 @default.
• W2058646840 hasConceptScore W2058646840C2777176818 @default.
• W2058646840 hasConceptScore W2058646840C2777669559 @default.
• W2058646840 hasConceptScore W2058646840C2779177272 @default.
• W2058646840 hasConceptScore W2058646840C2779951463 @default.
• W2058646840 hasConceptScore W2058646840C2781161787 @default.
• W2058646840 hasConceptScore W2058646840C530470458 @default.
• W2058646840 hasConceptScore W2058646840C71924100 @default.
• W2058646840 hasConceptScore W2058646840C87813604 @default.
• W2058646840 hasIssue "2" @default.

• next